Creating a vaccine using B-cells to fight Glioblastoma
Development of B-cell-based vaccine for Glioblastoma
This study is testing a new vaccine made from special immune cells to help boost the body's defense against Glioblastoma, a type of brain cancer, by making it easier for other immune cells to recognize and fight the tumor.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11037951 on NIH RePORTER |
What this research studies
This research focuses on developing a B-cell-based vaccine (BVax) aimed at enhancing the immune response against Glioblastoma (GBM). The vaccine is created from activated B cells that are engineered to stimulate T cells, which are crucial for attacking tumor cells. The study investigates how these B cells can effectively present antigens and promote the survival of T cells, potentially leading to improved anti-tumor immunity. The researchers are also exploring the mechanisms behind this immune response to optimize the treatment for future clinical use.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Glioblastoma who have not responded to existing immunotherapies.
Not a fit: Patients with other types of brain tumors or those who have already benefited from current immunotherapy treatments may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new immunotherapy option for patients with Glioblastoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results with similar immunotherapeutic approaches, indicating potential for success in this novel application.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Lee Chang, Catalina — Northwestern University at Chicago
- Study coordinator: Lee Chang, Catalina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.